Bio-Techne Corp (NASDAQ:TECH) Director Roger C. Lucas sold 100 shares of the business’s stock in a transaction on Tuesday, October 10th. The stock was sold at an average price of $121.96, for a total transaction of $12,196.00. The transaction was disclosed in a document filed with the SEC, which is available through this link.
Bio-Techne Corp (NASDAQ:TECH) last issued its earnings results on Tuesday, August 8th. The biotechnology company reported $1.09 EPS for the quarter, topping the consensus estimate of $0.99 by $0.10. The firm had revenue of $156.60 million during the quarter, compared to analysts’ expectations of $150.25 million. Bio-Techne Corp had a return on equity of 14.19% and a net margin of 12.93%. Bio-Techne Corp’s quarterly revenue was up 16.2% compared to the same quarter last year. During the same period last year, the business earned $0.92 earnings per share.
TRADEMARK VIOLATION WARNING: This piece was published by TrueBlueTribune and is the sole property of of TrueBlueTribune. If you are reading this piece on another publication, it was illegally copied and republished in violation of United States and international trademark & copyright laws. The legal version of this piece can be accessed at https://www.truebluetribune.com/2017/10/13/bio-techne-corp-tech-director-roger-c-lucas-sells-100-shares.html.
Several research firms recently issued reports on TECH. Zacks Investment Research raised shares of Bio-Techne Corp from a “hold” rating to a “buy” rating and set a $131.00 price target on the stock in a report on Thursday, July 6th. BidaskClub cut shares of Bio-Techne Corp from a “buy” rating to a “hold” rating in a report on Sunday, July 16th. Wells Fargo & Company began coverage on shares of Bio-Techne Corp in a report on Thursday, July 13th. They issued a “market perform” rating on the stock. Finally, Deutsche Bank AG upped their price target on shares of Bio-Techne Corp from $130.00 to $132.00 and gave the company a “buy” rating in a report on Wednesday, August 9th. Two investment analysts have rated the stock with a hold rating and five have issued a buy rating to the company. The stock currently has an average rating of “Buy” and an average target price of $128.75.
A number of hedge funds have recently modified their holdings of TECH. BlackRock Inc. lifted its position in Bio-Techne Corp by 14,548.6% in the first quarter. BlackRock Inc. now owns 3,500,436 shares of the biotechnology company’s stock worth $355,820,000 after purchasing an additional 3,476,540 shares during the period. Janus Henderson Group PLC lifted its holdings in shares of Bio-Techne Corp by 334.3% during the second quarter. Janus Henderson Group PLC now owns 1,188,108 shares of the biotechnology company’s stock valued at $139,603,000 after acquiring an additional 914,554 shares during the period. American Century Companies Inc. lifted its holdings in shares of Bio-Techne Corp by 174.8% during the second quarter. American Century Companies Inc. now owns 731,589 shares of the biotechnology company’s stock valued at $85,962,000 after acquiring an additional 465,398 shares during the period. Koch Industries Inc. bought a new position in shares of Bio-Techne Corp during the second quarter valued at $286,000. Finally, Schroder Investment Management Group lifted its holdings in shares of Bio-Techne Corp by 222.0% during the second quarter. Schroder Investment Management Group now owns 342,815 shares of the biotechnology company’s stock valued at $40,220,000 after acquiring an additional 236,362 shares during the period. 98.40% of the stock is owned by hedge funds and other institutional investors.
Bio-Techne Corp Company Profile
Bio-Techne Corporation develops, manufactures and sells biotechnology reagents and instruments for the research and clinical diagnostic markets. The Company operates through three segments: Biotechnology, Clinical Controls and Protein Platforms. The Biotechnology segment develops, manufactures and sells biotechnology research and diagnostic products, such as cytokines, growth factors, immunoassays, antibodies and related reagents, across the world.
Receive News & Ratings for Bio-Techne Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Techne Corp and related companies with MarketBeat.com's FREE daily email newsletter.